Page 84 - Genentech News Today

Editor’s Note: In our recent white paper, Achieving Clinical Trial Diversity: Expanding Hospital Capacity to Offer Trials in the Community, Manatt Health discusses the important role...

Article: Pink Slime is Still in Meat Supply--Unlabeled - In my new book Click I discuss the opioid scandals newer drugs with 5 and 6 figure price tags the move toward, danger and reasons for faster drug approvals and the return of pink slime in the food supply

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week.

Before multinational life science firms like Genentech, Amgen and Abbvie dotted the eastern side of Highway 101, the industrial city of South San Francisco was home to a thriving manufacturing

The U.S.

Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These...

Genentech announced the FDA had approved faricimab-svoa (Vabysmo) for retinal vein occlusion on October 26, 2023, which marks the third ophthalmic indication for the bispecific antibody.

Faricimab is the first and only bispecific antibody granted FDA approval for treatment of the eye.

The FDA has approved Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion.

After 1 year of treatment with risdiplam, 81% of the 26-infant cohort was able to sit independently for 30 seconds, a milestone not typically reached in spinal muscular atrophy (SMA).